SEC Form 4 · accession 0001159036-26-000095
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Darren Snellgrove
Officer — SVP, Chief Financial Officer
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 4:44 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001159036
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1 | $0.00 | Jul 1, 2026 | A | 41,554 | A | Jul 1, 2027 | — | Common Stock | 41,554 | 41,554 | D |
| Option to Purchase Common StockF2 | $77.01 | Jul 1, 2026 | A | 127,432 | A | Jul 1, 2027 | Jul 1, 2036 | Common Stock | 127,432 | 127,432 | D |
Explanation of responses
- F1This award vests one-third on the first anniversary of the grant date and then one-third on each anniversary date thereafter.
- F2This option vests one-fourth on such date and then 1/48th monthly thereafter.